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Abstract
Background: Anti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal
cancers; however, its efficacy in pMMR gastric cancers remains undetermined. Here, we report the case of a patient
with pMMR and microsatellite-stable gastric cancer who exhibited a partial response to salvage anti-programmed
death-1 therapy with pembrolizumab.
Case presentation: Initially, the patient underwent subtotal gastrectomy 4 years ago for early-stage gastric cancer
(pT1bN2M0, stage IIA). Immunohistochemical analysis of the tumor revealed strongly positive for HER2/neu. He had
received trastuzumab plus pertuzumab, cisplatin, and capecitabine for recurrent tumors since September 2014 for
15 cycles. Disease progression of gastric cancer was found in August 2015. Since September 2015, the patient has
received pembrolizumab monotherapy (200 mg as a fixed dose, every 3 weeks) for 3 months and the repeat
computed tomography demonstrated a confirmed partial response. The plasma carcinoembryonic antigen also
decreased dramatically. Both immunohistochemistry and a polymerase chain reaction-based method revealed that
the patient had pMMR gastric cancer.
Conclusions: This case report provides the first report that mismatch repair-proficient and microsatellite-stable
gastric cancers can respond well to anti-PD-1 monotherapy and indicates both markers may not sufficiently be
predictive of anti-PD-1 therapy resistance in gastric cancer.
Keywords: Gastric cancer, Immunotherapy, Anti-programmed death-1 antibody, Mismatch repair deficiency,
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Background
Immune checkpoint blockade therapies such as those
using anti-cytotoxic T lymphocyte-associated protein 4
antibodies and those blocking programmed death-1
(PD-1) and programmed death ligand-1 (PD-L1) have
exhibited promising efficacy in several types of cancer
[1–7]. Moreover, the heterogeneous response to immune
checkpoint blockade therapy observed in patients in
these studies has raised the importance of identifying
predictive biomarkers. Mutation or hypermethylation in
mismatch repair genes (MLH1, MSH2, MSH6, or PMS2)
leads to deficient mismatch repair (dMMR) and causes
accumulation errors in DNA sequences, thus increasing
the risk of colorectal cancer (CRC) and other epithelial
cancers [8]. Recently, Le et al. reported that patients
with mismatch repair-deficient CRC and those with mis-
match repair-deficient noncolorectal cancer exhibited
higher response rates to PD-1 blockade monotherapy
(pembrolizumab). In addition, they suggested that hyper-
mutated tumor-associated neoantigens from dMMR are
the primary factors affecting the response to anti-PD-1
therapy; previous studies have observed that this therapy
stimulated the endogenous immune response [3, 9, 10].
However, Le et al. also reported that none of 18 patients
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with mismatch repair-proficient (pMMR) CRC res-
ponded to pembrolizumab, an anti-PD-1 antibody. The
efficacy of PD-1 blockade therapy in pMMR noncolorec-
tal cancers and a biomarker for PD-1 blockade remain
unknown. Here, we report the case of a 64-year-old man
with pMMR and microsatellite-stable (MSS) gastric
cancer who exhibited a partial response to salvage pem-
brolizumab monotherapy.
Case presentation
A 64-year-old man experienced epigastralgia with tarry
stool in late 2011. Esophagogastroduodenoscopy re-
vealed a circular ulcer in the prepyloric area. Biopsy was
performed, and the pathology of the specimen revealed
gastric adenocarcinoma. On the basis of computed tom-
ography (CT), the gastric cancer was clinically staged as
cT3N0M0, stage IIA. He underwent radical subtotal gas-
trectomy, Billroth II anastomosis, D2 dissection, and
cholecystectomy on December 28, 2011. The pathology
of the specimen revealed a well-differentiated adeno-
carcinoma, and Helicobacter pylori infection was not
observed (Fig. 1a). Immunohistochemically, tumor cells
were strongly positive (3+, according to the proposal by
Hofmann et al. [11]) for HER2/neu immunostain (clone
4B5, 1:2 dilution; Fig 1b). The pathological staging of the
gastric cancer was pT1bN2M0, stage IIA. After surgery,
he was followed up regularly at our hospital without ad-
juvant treatment.
Two years later, CT and positron emission tomography
revealed tumor recurrence in the left lower paratracheal
lymph nodes. The patient was then enrolled in a clinical
trial and received 15 cycles of pertuzumab (840 mg on
D1, every 3 weeks) in combination with trastuzumab
(562 mg on D1, every 3 weeks) and chemotherapy
(80 mg/m2 cisplatin on D1 and 1000 mg/m2 capecita-
bine twice a day on D1–D14, every 3 weeks). He was
dropped from the study in August 2015 because the
tumors (peritoneal seeding and paraaortic lymph nodes)
progressed and his plasma carcinoembryonic antigen
(CEA) level increased from 4.78 to 348 ng/mL. The best
response of the treatment was stable disease with a first-
line progression-free survival of 11 months.
In September 2015, the patient started receiving pem-
brolizumab (200 mg as a fixed dose, every 3 weeks) as a
second-line treatment for recurrent gastric cancer. No
adverse event was observed in the following 2–3 months.
Two months later, CT revealed tumor regression and a
partial response was confirmed in another CT scan
1 month later (Fig. 2). In addition, the plasma CEA level
decreased from 607.1 to 26.96 ng/mL. To investigate the
association of the tumor factors with the efficacy of PD-
1 blockade as well as to confirm whether he had pMMR
gastric cancer, we used both immunohistochemistry
(IHC) and a polymerase chain reaction-based method
(Fig. 3) [12]. In addition, we performed IHC analyses of
previous specimens from gastrectomy, which revealed
few tumor-infiltrating lymphocytes (TILs) in tumors and
invasive fronts, as demonstrated by the presence of CD3
(polyclonal, 1:100), CD4 (clone MT310, 1:50), and CD8
(clone DK-25, 1:200; Fig. 4a–c). Epstein–Barr virus
(EBV)-encoded small RNA (EBER) in situ hybridization
revealed absence of EBV in the tumor cells (Fig. 4d).
The tumor cells were also negative for PD-L1 (B7H1,
Abcam, clone ab58810, 1:400; Fig. 5) [13]. Moreover, no
polymerase epsilon (POLE) mutation was found by
means of Sanger sequencing of exon 9. As of January
2016, the patient was still continuing the pembrolizumab
monotherapy with excellent performance status and
quality of life.
Discussion
Evaluations of the efficacy of PD-1 blockade in advanced
esophagogastric junction (EGJ) and gastric adenocarcin-
oma are still preliminary, and an accurate predictive bio-
marker remains to be determined. Bang et al. reported
that the overall response rate of pembrolizumab (by cen-
tral review) in advanced PD-L1-positive gastric cancer was
22.2 % [95 % confidence interval, 10.1–39.2] in a phase I
study (KEYNOTE-012 study, gastric cancer cohort) [14].
Of the 162 patients screened, 65 were positive for PD-L1.
Fig. 1 Histopathology of the gastric cancer and its HER2 immunohistochemistry. Microscopic observation revealed a well-differentiated adenocarcinoma
with frequent luminal formation and evident nuclear atypia infiltration within a mild desmoplastic stroma; H & E stain (a). In the metastasized lymph node,
the tumor cells were strongly positive for the HER2/neu immunostain (brown color) (b); original magnification ×100
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The PD-L1 expression was detected through a prototype
IHC assay by using the 223C antibody, and the tumors
were determined positive for PD-L1 when PD-L1 staining
was observed in the stroma or ≥1 % of tumor nest cells.
However, PD-L1 expression is not yet a validated pre-
dictive biomarker for PD-1 blockade in gastric cancer.
Moreover, dMMR has been identified in gastric cancer in
several studies with the incidence ranging from 9 to 22 %
[15–19]. In a study conducted using the Cancer Genome
Atlas (TCGA), 22 % of the tumors belonged to the micro-
satellite instability (MSI) subtype, with the features of
hypermutation and MLH1 silencing. Although pMMR has
been shown to predict poor efficacy of PD-1 blockade in
CRC, the association of pMMR and PD-1 blockade in EGJ
and gastric adenocarcinoma remains unknown. This case
report provides the first report that pMMR and MSS
gastric cancers can respond well to anti-PD-1 monother-
apy. However, larger studies are warranted to explore the
association between mismatch repair status and the effi-
cacy of anti-PD-1 therapy in advanced gastric cancer.
The hypothesis that neoantigens from hypermutated
tumors may enhance the response of immune check-
point therapy was supported by clinical correlative
studies on melanoma and non-small-cell lung cancer
[3, 20, 21]. In addition to dMMR, inactivating POLE
mutation, found in CRC, endometrial cancer, and gastric
cancer, can result in an extremely high mutation burden
[15, 22, 23]. Howitt et al. demonstrated that increased
TILs in the tumor microenvironment in POLE-mutated
endometrial cancers make these tumors satisfactory candi-
dates for immune checkpoint therapy [23]. We cannot
completely exclude the possibility that our patient
had a POLE-mutated tumor; however, the incidence
of POLE mutation in gastric cancer is very low
(0.47 %) and TILs in the tumor microenvironment
were scant in our patient [15].
Fig. 2 Computed tomography scan of the recurrent tumors before and after pembrolizumab treatment
Fig. 3 Immunohistochemistry of MMR protein. The tumor cells preserved expression of MLH1 (a), MSH2 (b), PMS2 (c), and MSH6 (d); original
magnification ×400
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PD-L1 has been reported to be overexpressed in
EBV-associated malignancies, such as EBV-associated
lymphoproliferative diseases, nasopharyngeal carcin-
oma, and HHV8-associated primary effusion lymph-
oma [24, 25]. The mechanisms underlying increased
PD-L1 expression in Hodgkin lymphoma include genetic
amplification of CD274 (encoding PD-L1) and constitutive
AP1 signaling. The TCGA study also revealed that the
amplification of CD274 and PDCD1LG2 (also encoding
PD-L1 and PD-L2) was enhanced in the EBV-positive
gastric cancer subgroup [15]. Thus, these cancers are
attractive targets for immune checkpoint therapy. In our
patient, EBER in situ hybridization revealed absence of
EBV in the tumor cells, and it is unlikely that the efficacy
of anti-PD-1 therapy is affected by EBV-related CD274
and PDCD1LG2 amplification.
Conclusions
In conclusion, we report the case of a patient with
pMMR and MSS gastric cancer who exhibited a con-
firmed objective response to PD-1 blockade, pembro-
lizumab monotherapy. Our case report indicates that
mismatch repair proficiency and microsatellite stability
may not be predictive to resistance of anti-PD-1 therapy,
and factors other than dMMR and EBV infection may
contribute to the response to anti-PD-1 therapy.
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Fig. 4 Tumor-infiltrating lymphocytes and EBV status. The invasive front is highlighted by a yellow dashed line, which separates the tumor part (T)
from the nontumor part (NT). Few CD3(+) tumor-infiltrating lymphocytes (brown spot) (a). The infiltrating CD3(+) cells were composed mainly of
CD4(+) cells (brown spot) (b) and a few CD8(+) cells (brown spot) (c). The invasive front had only a few lymphocytes. Most of the lymphocytes
were scattered between tumor nests rather than within tumor nests. EBER in situ hybridization revealed no evidence of EBV infection in the tumor
cells (positive is denoted by a dark blue spot in nuclei) (d); original magnification: ×100
Fig. 5 Immunohistochemistry of PD-L1 protein. The tumor cells were
negative for PD-L1 (B7-H1); original magnification ×400
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